FDA CRACKDOWN on Compounded GLP-1s | Novo’s Gut Hack & Lilly’s One-Shot Cure
Update: 2025-09-09
Description
🚨 FDA cracks down on compounded GLP-1 medications, raising questions about the future safety, quality, supply, and cost. In this episode of On The Pen Live, we break down what the FDA’s new “green list” means for patients relying on compounded semaglutide and tirzepatide, including risks like dosing errors, unapproved salt forms, and hospitalizations.
We also cover two massive research moves shaking up the future of obesity and diabetes care:
✅ Novo Nordisk + Novonesis team up on gut microbiome therapies, using probiotics and prebiotics (synbiotics) to prevent obesity and improve blood sugar and cholesterol.
✅ Eli Lilly + Remedium Bio launch a gene therapy partnership that could replace weekly GLP-1 injections with a single, long-acting shot.
PLUS: An exclusive interview with Alicia, cofounder of Claimable, about the class action lawsuit against CVS Caremark for forcing patients to switch from Zepbound to Wegovy. We talk timelines, how to get involved, and what it means for patient choice in obesity treatment.
We also cover two massive research moves shaking up the future of obesity and diabetes care:
✅ Novo Nordisk + Novonesis team up on gut microbiome therapies, using probiotics and prebiotics (synbiotics) to prevent obesity and improve blood sugar and cholesterol.
✅ Eli Lilly + Remedium Bio launch a gene therapy partnership that could replace weekly GLP-1 injections with a single, long-acting shot.
PLUS: An exclusive interview with Alicia, cofounder of Claimable, about the class action lawsuit against CVS Caremark for forcing patients to switch from Zepbound to Wegovy. We talk timelines, how to get involved, and what it means for patient choice in obesity treatment.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
